68ga-psma ligand pet/ct-based radiotherapy for lymph node relapse of prostate cancer after primary therapy delays initiation of systemic therapy

Anticancer Research

Volumn 37, Issue 3, 2017, Pages 1273-1280

  Henkenberens, Christoph ^a   Von Klot, Christoph A ^b   Ross, Tobias L ^c   Bengel, Frank M ^c   Wester, Hans Jürgen ^d   Katja, Hüper ^a   Christiansen, Hans ^a   Derlin, Thorsten ^c  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b Department of Urology and Urologic Oncology ^*  (Germany)

^c University Vim   (Germany)

^d TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

Lymph node metastases; PSMA PET CT; Radiotherapy; Recurrent prostate cancer; Systemic therapy

Indexed keywords

PROSTATE SPECIFIC MEMBRANE ANTIGEN LIGAND GA 68; TRACER; UNCLASSIFIED DRUG; GALLIUM; GLUTAMATE CARBOXYPEPTIDASE II; GLUTAMATE CARBOXYPEPTIDASE II, HUMAN; LIGAND; MEMBRANE ANTIGEN; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ANDROGEN DEPRIVATION THERAPY; ARTICLE; BIOCHEMICAL FAILURE FREE SURVIVAL; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL OUTCOME; CONFORMAL RADIOTHERAPY; DIARRHEA; FOLLOW UP; HUMAN; LOCAL THERAPY; LYMPH NODE METASTASIS; MALE; MIDDLE AGED; OVERALL SURVIVAL; PARAAORTIC LYMPH NODE; PELVIS LYMPH NODE; PET-CT SCANNER; POSITRON EMISSION TOMOGRAPHY-COMPUTED TOMOGRAPHY; PRIORITY JOURNAL; PROSTATE CANCER; RADIATION FIELD; RADIOTHERAPY PLANNING SYSTEM; RE-IRRADIATION; SYSTEMIC THERAPY; THERAPY DELAY; BLOOD; CANCER STAGING; CHEMISTRY; DIAGNOSTIC IMAGING; PATHOLOGY; PROSTATIC NEOPLASMS; RECURRENT DISEASE; TIME TO TREATMENT; TREATMENT OUTCOME; TUMOR RECURRENCE; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANTIGENS, SURFACE; GALLIUM RADIOISOTOPES; GLUTAMATE CARBOXYPEPTIDASE II; HUMANS; LIGANDS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; POSITRON EMISSION TOMOGRAPHY COMPUTED TOMOGRAPHY; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RECURRENCE; TIME-TO-TREATMENT; TREATMENT OUTCOME;

EID: 85015827737     PISSN: 02507005     EISSN: 17917530     Source Type: Journal    
DOI: 10.21873/anticanres.11444     Document Type: Article

References (31)

1. Picchio M, Berardi G, Fodor A, Busnardo E, Fiorino C, Kirienko M, Incerti E, Messa C, Gianoli L and di Muzio N: (11)C-Choline PET/CT as a guide to radiation treatment planning of lymphnode relapses in prostate cancer patients. Eur J Nucl Med Mol Imaging 41: 1270-1279, 2014.
2. Ost P, Decaestecker K, Lambert B, Fonteyne V, Delrue L, Lumen N, Ameye F and de Meerleer G: Prognostic factors influencing prostate cancer-specific survival in non-castrate patients with metastatic prostate cancer. Prostate 74: 297-305, 2013.
3. Mottet N, Bellmunt J, Bolla M, Joniau S, Matveev V, Schmid HP, Van der Kwast T, Wiegel T and Zattoni F: EAU guidelines on prostate cancer part II: treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol 59: 572-883, 2011.
4. Henkenberens C, Merseburger AS, Bengel F, Derlin T, Hueper K, Grünwald V and Christiansen H: Radiotherapy for isolated lymph node metastases in patients with locally advanced prostate cancer after primary therapy. World J Urol 34: 1239-1245, 2016.
5. Grosu A-L, Piert M, Weber MA, Jeremic B, Picchio M, Schratzenstaller U, Zimmermann FB, Schwaiger M and Molls M: Positron-emission tomography for radiation treatment planning. Strahlenther Onkol 181: 483-499, 2005.
6. Von Eyben FE and Kairemo K: Meta-analysis of 11C-choline and 18F-choline PET/CT for management of patients with prostate cancer. Nucl Med Commun 35: 221-230, 2014.
7. Mease RC, Foss CA and Pomper MG: PET imaging in prostate cancer: focus on prostate-specific membrane antigen. Curr Top Med Chem 13: 951-962, 2013.
8. Henkenberens C, von KLot CA, Ross TL, Bengel FM, Wester HJ, Merseburger AS, Vogel-Claussen J, Christiansen H and Derlin T: 68Ga-PSMA ligand PET/CT-based radiotherapy in locally recurrent and recurrent oligometastatic prostate cancer: Early efficacy after primary therapy. Strahlenther Onkol 192: 431-439, 2016.
9. Chang SS, O'Keefe DS, Bacich DJ, Reuter VE, Heston WD and Gaudin PB: Prostate-specific membrane antigen is produced in tumor-associated neovasculature. Clin Cancer Res 5: 2674-2881, 1999.
10. Afshar-Oromieh A, Zechman CM, Malcher A, Eder M, Eisenhut M, Linhart HG, Holland-Letz T, Hadaschik BA, Giesel FL, Debus J and Haberkorn U: Comaparison of PET imaging with a (68) Ga-labelled PSMA ligand and (18)F-choline-based PET/CT for the diagnosis of recurrent prostate cancer. Eur J Nucl Mol Imaging 41: 11-20, 2014.
11. Weineisen M, Schottelius M, Simecek J, Baum RP, Yildiz A, Beykan S, Kulkarni HR, Lassmann M, Eiber M, Schwaiger M and Wester HJ: 68Ga-and 177Lu-labeled PSMA I&T: Optimization of a PSMA-targeted theranostic concept and first proof-of-concept human studies. J Nucl Med 56: 1169-1176, 2015.
12. Martin R, Jüttler S, Müller M and Wester HJ: Cationic eluate pretreatment for automated synthesis of [68GA] CPCR4.2. Nucl Med Biol 41: 84-89, 2014.
13. Herrmann K, Bluemel C, Weineisen M, Schottelius M, Wester HJ, Czernin J, eberlein U, Beykan S, Lapa C, Riedmiller H, Krebs M, Kropf S, Schirbel A, Buck AK and Lassmann M: Biodistribution and radiation dosimetry for a probe targeting prostate-specific membrane antigen for imaging and therapy. J Nucl Med 56: 855-861, 2015.
14. National Cancer Institute: Common Terminology Criteria for Adverse Events (CTCAE)v.4.0.http://ctep.cancer.gov/protocol Development/electronic-applications/ctc.htm. Last accessed 23 December, 2016
15. Pavy JJ, Denekamp J, Letschert J, Littbrand B, Momex F, Bernier J, Gonzales-Gonzales D, Horiot JC, Bolla M and Bartelink H: EORTC Late Effects Working Group. Late effects toxicity scoring: the SOMA scale. Int J Radiat Oncol Biol Phys 31: 1043-1047, 1995.
16. Rauscher I, Maurer T, Beer AJ, Graner FP, Haller B, Weirich G, Doherty A, Gschwend JE, Schwaiger M and Eiber M: Value of 68Ga-PSMA HBED-CC PET for the assessment of lymph node metastases in prostate cancer patients woth biochemical recurrence with histopathology after salvage lymhadenectomy. J Nucl Med 57: 1713-1719, 2016.
17. van Leeuwen PJ, Emmet L, Ho B, Delprado W, Ting F, Ngyuen Q and Sticker P: Prospective Evaluation of 68gallium-PSMA positron emission tomography/computerized tomography for preoperative lymph node staging in prostate cancer .BJU Int 119: 209-215, 2017.
18. van Leeuwen PJ, Stricker P, Hruby G, Kneebone A, Ting F, Thompson B, Nguyen Q, Ho B and Emett L: (68) Ga-PSMA has a high detection rate of prostate cancer recurrence outside the prostatic fossa in patients being considered for salvage radiation treatment. BJU Int 117: 732-739, 2016.
19. Afshar-Oromieh A, Avtzi E, Giesel FL, Holland-Letz T, Linhart HG, Eder M, Eisenhut M, Boxler S, Hadaschick BA, Kratochwil C, Weichert W, Kopka K, Debus J and Haberkorn U: The diagnostic value of PET/CT imaging with the (68)Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer. Eur J Nucl Med Mol Imaging 42: 197-209, 2015.
20. Giesel FL, Fiedler H, Stefanova M, Sterzing F, Rius M, Kopka K, Moltz JH, Afshar-Oromieh A, Choyke PL, Haberkorn U and Kratochwil C: PSMA PET/CT with Glu-urea-Lys-(Ahx)-[68Ga(HBED-CC)] versus 3D CT volumetric lymph node assessment in recurrent prostate cancer. Eur J Nucl Med Mol Imaging 42: 1794-1800, 2015.
21. Ceci F, Uprimny C, Nilica B, Geraldo L, Kendler D, Kroiss A, Bektic J, Horninger W, Lukas P, Decristoforo C, castellucci P, Fanti S and Virgolini IJ: (68)Ga-PSMA PET/CT for restaging recurrent prostate cancer: Which factors are associated with PET/CT detection rate? Eur J Nucl Med Mol Imaging 42: 1784-1794, 2015.
22. Yu EY, Gulati R, Telesca D, Jiang P, Tam S, Russel KJ, Nelson PS, Etzioni RD and Higano CS: Duration of first off-treatment interval is prognostic for time to castration resistance an death in men with biochemical relapse of prostate cancer treated on a prospective trial of intermittent androgen deprivation. J Clin Oncol 28: 2668-2773, 2010.
23. Joensuu T, Joensuu G, Kairemo K, Kiljunen T, Riener M, Aaltonen A, Ala-Opas M, Kangasmäki A, Alanko T, Taipale L, hervonen P, Bützow A, Virgolini I and Hemminki A: Multimodal primary treatment of metastatic prostate cancer with androgen deprivation and radiation. Anticancer Res 36: 6439-6447, 2016.
24. Punnen S, Cooperberg MR, D'Amic AV, Karakiewicz PI, Moul JW, Scher HI, Schlomm T and Freedland SJ: Management of biochemical recurrence after primary treatment of prostate cancer: a systematic review of the literature: Eur Urol 64: 905-915, 2013.
25. Jilg CA, Rischke HC, Reske SN, Henne K, Grosu AL, Weber W, drendel V, Schwardt M, Jandausch A and Schultze-Seeman W: Salvage lymph node dissection with adjuvant radiotherapy for nodal recurrence of prostate cancer. J Urol 188: 2190-2197, 2012.
26. Rischke HC, Schultze-Seemann, Wieser G, Krönig M, Drendel V, Stegmaier P, Krauss T, Henne K, Volegova-Neher N, Schlager D, Kirste S, Grosu Al and Jilg CA: Adjuvant radiotherapy after salvage lymph node dissection because of nodal relapse of prostate cancer versus salvage lymph node dissection only. Strahlenther Onkol 191: 310-320, 2015.
27. Suardi N, Gandaglia G, Gallina A, Di Trapani E, Scattoni V, Vizziello D, Cucchiara V, Bertini R, Colombo R, Picchio M, Giovacchini G, Montorsi F and Briganti A: Long-term outcomes of salvage lymph node dissection for clinically recurrent prostate cancer: results of a single-institution series with a minimum follow-up of 5 years. Eur Urol 67: 299-309, 2015.
28. Rinnab L, Mottaghy FM, Simon J, Volkmer BG, de Petriconi R, Hautmann RE Wittbrodt M, Egghart G, Moeller P, Blumstein N, Reske S and Kuefer R: [11C] Choline PET/CT for targeted salvage lymph node dissection in patients with biochemical recurrence after primary curative therapy for prostate cancer. Preliminary results of a prospective study. Urol Int 81: 191-197, 2008.
29. Niyazi M, Bartenstein P, Belka C and Ganswindt U: Choline PET based dose-painting in prostate cancer-modelling of dose effects. Radiat Oncol. 2010;18;5:23. doi: 10.1186/1748-717X-5-23
30. Schick U, Jorcano S, Nouet P, Rouzrad M, Vees H, Zilli T, Ratib O, Weber Dc and Miralbell R: Androgen deprivation and highdose radiotherapy for oligometastatic prostate cancer patients with less than five regional and/or distant metastasis. Acta Oncol 52: 1622-1628, 2013.
31. Heck MM, Retz M, D'Alessandria C, Rauscher I, Scheidhauer K, Maurer T, Storz E, Janssen F, Schottelius M, Wster HJ, Gschwend JE, Schwaiger M, Tauber R and Eiber M: Systemic radioligand therapy with 177Lu-labeled prostate-specific membrane antigen ligand for imaging and therapy in patients with metastatic castration resistant prostate cancer. J Urol 196: 382-391, 2016